Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib/binimetinib continuation master protocol
NL-OMON53566Phase 4Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of binimetinib and encorafenib in melanoma, Serous Papillary Cystadenocarcinoma, fallopian tube serous adenocarcinoma (FTC) and 2 more (3 arms), sponsored by Pfizer. Primary endpoints: Adverse events leading to permanent discontinuation and Serious adverse events. Started Jan 2023; status: recruiting.
02
Drugs
binimetinibencorafenib
03
Conditions
melanomaSerous Papillary Cystadenocarcinomafallopian tube serous adenocarcinoma (FTC)serous peritoneal carcinoma (PPSC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53566.